ATE315031T1 - 2,4-disubstierte triazinderivate mit anti-hiv aktivität - Google Patents

2,4-disubstierte triazinderivate mit anti-hiv aktivität

Info

Publication number
ATE315031T1
ATE315031T1 AT99953980T AT99953980T ATE315031T1 AT E315031 T1 ATE315031 T1 AT E315031T1 AT 99953980 T AT99953980 T AT 99953980T AT 99953980 T AT99953980 T AT 99953980T AT E315031 T1 ATE315031 T1 AT E315031T1
Authority
AT
Austria
Prior art keywords
triazine derivatives
hiv activity
disubstituted triazine
disubstituted
hiv
Prior art date
Application number
AT99953980T
Other languages
English (en)
Inventor
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Paul Adriaan Jan Janssen
Robert W Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Aken Koen Jeanne Alfons Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE315031T1 publication Critical patent/ATE315031T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
AT99953980T 1998-11-10 1999-11-04 2,4-disubstierte triazinderivate mit anti-hiv aktivität ATE315031T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10779998P 1998-11-10 1998-11-10
EP99203128 1999-09-24

Publications (1)

Publication Number Publication Date
ATE315031T1 true ATE315031T1 (de) 2006-02-15

Family

ID=26153374

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953980T ATE315031T1 (de) 1998-11-10 1999-11-04 2,4-disubstierte triazinderivate mit anti-hiv aktivität

Country Status (35)

Country Link
US (2) US6638932B1 (de)
EP (1) EP1129079B1 (de)
JP (1) JP2002529457A (de)
KR (1) KR100620402B1 (de)
CN (1) CN1207290C (de)
AP (1) AP1636A (de)
AR (1) AR021137A1 (de)
AT (1) ATE315031T1 (de)
AU (1) AU764472B2 (de)
BG (1) BG65160B1 (de)
BR (1) BR9915176A (de)
CA (1) CA2351203C (de)
CY (1) CY1105596T1 (de)
CZ (1) CZ20011532A3 (de)
DE (1) DE69929354T2 (de)
DK (1) DK1129079T3 (de)
EA (1) EA004501B1 (de)
EE (1) EE200100253A (de)
ES (1) ES2257081T3 (de)
HK (1) HK1038232A1 (de)
HR (1) HRP20010310A2 (de)
HU (1) HUP0104395A3 (de)
ID (1) ID28545A (de)
IL (2) IL143024A0 (de)
MY (1) MY126781A (de)
NO (1) NO319788B1 (de)
NZ (1) NZ510919A (de)
OA (1) OA11675A (de)
PL (1) PL196523B1 (de)
PT (1) PT1129079E (de)
SI (1) SI1129079T1 (de)
SK (1) SK6022001A3 (de)
TR (1) TR200101319T2 (de)
TW (1) TW541305B (de)
WO (1) WO2000027828A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510919A (en) * 1998-11-10 2003-11-28 Janssen Pharmaceutica Nv 2,4-disubstituted triazine derivatives
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
ES2542326T3 (es) 2000-05-08 2015-08-04 Janssen Pharmaceutica Nv Inhibidores de la replicación del VIH
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
MXPA05008368A (es) * 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
RU2401833C2 (ru) 2004-08-10 2010-10-20 Янссен Фармацевтика Н.В. Производные 1, 2, 4-триазин-6-она, ингибирующие вич
GB201204756D0 (en) * 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4927592B1 (de) * 1970-05-13 1974-07-18
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US4650867A (en) * 1985-03-26 1987-03-17 Ciba-Geigy Corporation Process for the preparation of 2,4,6-tris(aminophenylamino)triazines
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
NZ510919A (en) * 1998-11-10 2003-11-28 Janssen Pharmaceutica Nv 2,4-disubstituted triazine derivatives

Also Published As

Publication number Publication date
DE69929354T2 (de) 2006-09-14
HRP20010310A2 (en) 2002-06-30
US6638932B1 (en) 2003-10-28
MY126781A (en) 2006-10-31
SI1129079T1 (sl) 2006-06-30
EA004501B1 (ru) 2004-04-29
CA2351203A1 (en) 2000-05-18
BG105419A (en) 2001-11-30
KR100620402B1 (ko) 2006-09-13
US7015221B2 (en) 2006-03-21
TW541305B (en) 2003-07-11
HUP0104395A2 (hu) 2002-04-29
EP1129079A2 (de) 2001-09-05
NO319788B1 (no) 2005-09-12
TR200101319T2 (tr) 2001-10-22
JP2002529457A (ja) 2002-09-10
CY1105596T1 (el) 2010-07-28
DE69929354D1 (de) 2006-03-30
CN1325387A (zh) 2001-12-05
AU764472B2 (en) 2003-08-21
BG65160B1 (bg) 2007-04-30
PT1129079E (pt) 2006-05-31
IL143024A (en) 2006-06-11
US20050277641A1 (en) 2005-12-15
PL196523B1 (pl) 2008-01-31
AR021137A1 (es) 2002-06-12
EA200100534A1 (ru) 2001-10-22
WO2000027828A3 (en) 2000-09-21
CZ20011532A3 (cs) 2001-10-17
NZ510919A (en) 2003-11-28
EE200100253A (et) 2002-12-16
WO2000027828A2 (en) 2000-05-18
CN1207290C (zh) 2005-06-22
OA11675A (en) 2005-01-12
AU1046200A (en) 2000-05-29
CA2351203C (en) 2009-03-24
KR20010075234A (ko) 2001-08-09
BR9915176A (pt) 2001-08-14
ES2257081T3 (es) 2006-07-16
NO20011934D0 (no) 2001-04-19
HK1038232A1 (en) 2002-03-08
EP1129079B1 (de) 2006-01-04
ID28545A (id) 2001-05-31
PL348145A1 (en) 2002-05-06
HUP0104395A3 (en) 2003-02-28
DK1129079T3 (da) 2006-05-15
SK6022001A3 (en) 2002-01-07
AP1636A (en) 2006-07-17
IL143024A0 (en) 2002-04-21
NO20011934L (no) 2001-04-19

Similar Documents

Publication Publication Date Title
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
ATE275557T1 (de) 2-substituierte 4,5-diarylimidazole
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
NO990892D0 (no) Substituerte 6,6-hetero-bicykliske derivater
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE122005000003I1 (de) Heterocyclische Azahexanderivate mit Antiviraler wirkung.
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
ATE227282T1 (de) 2,4-diaminopyrimidin-derivate
NO20003825D0 (no) 1,3,4 - oxadiazolonderivater
ATE315031T1 (de) 2,4-disubstierte triazinderivate mit anti-hiv aktivität
DE69714358T2 (de) 9,10-disubstituierte campothecinderivate mit antitumoraktivität
DK1149106T3 (da) 4,5-azolo-oxindoler
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
DE69815072D1 (de) Substituierte 2,4-diaminopyrimidine
DZ2644A1 (fr) Triazolo-Ä3,4-aÜ-pyridazine substituées en 1,2,4.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129079

Country of ref document: EP

REN Ceased due to non-payment of the annual fee